Show simple item record

dc.contributor.authorWilde, Joshua T.
dc.contributor.authorSprings, Stacy
dc.contributor.authorWolfrum, Jacqueline M.
dc.contributor.authorLevi, Retsef
dc.date.accessioned2023-11-09T15:38:18Z
dc.date.available2023-11-09T15:38:18Z
dc.date.issued2023-09-29
dc.identifier.urihttps://hdl.handle.net/1721.1/152928
dc.description.abstractAbstract Introduction Postmarketing drug safety surveillance research has focused on the product-patient interaction as the primary source of variability in clinical outcomes. However, the inherent complexity of pharmaceutical manufacturing and distribution, especially of biologic drugs, also underscores the importance of risks related to variability in manufacturing and supply chain conditions that could potentially impact clinical outcomes. We propose a data-driven signal detection method called HMMScan to monitor for manufacturing lot-dependent changes in adverse event (AE) rates, and herein apply it to a biologic drug. Methods The HMMScan method chooses the best-fitting candidate from a family of probabilistic Hidden Markov Models to detect temporal correlations in per lot AE rates that could signal clinically relevant variability in manufacturing and supply chain conditions. Additionally, HMMScan indicates the particular lots most likely to be related to risky states of the manufacturing or supply chain condition. The HMMScan method was validated on extensive simulated data and applied to three actual lot sequences of a major biologic drug by combining lot metadata from the manufacturer with AE reports from the US FDA Adverse Event Reporting System (FAERS). Results Extensive method validation on simulated data indicated that HMMScan is able to correctly detect the presence or absence of variable manufacturing and supply chain conditions for contiguous sequences of 100 lots or more when changes in these conditions have a meaningful impact on AE rates. Applying the HMMScan method to FAERS data, two of the three actual lot sequences examined exhibited evidence of potential manufacturing or supply chain-related variability. Conclusions HMMScan could be utilized by both manufacturers and regulators to automate lot variability monitoring and inform targeted root-cause analysis. Broad application of HMMScan would rely on a well-developed data input pipeline. The proposed method is implemented in an open-source GitHub repository.en_US
dc.publisherSpringer International Publishingen_US
dc.relation.isversionofhttps://doi.org/10.1007/s40264-023-01349-6en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourceSpringer International Publishingen_US
dc.titleDevelopment and Application of a Data-Driven Signal Detection Method for Surveillance of Adverse Event Variability Across Manufacturing Lots of Biologicsen_US
dc.typeArticleen_US
dc.identifier.citationWilde, Joshua T., Springs, Stacy, Wolfrum, Jacqueline M. and Levi, Retsef. 2023. "Development and Application of a Data-Driven Signal Detection Method for Surveillance of Adverse Event Variability Across Manufacturing Lots of Biologics."
dc.contributor.departmentMassachusetts Institute of Technology. Operations Research Center
dc.contributor.departmentMassachusetts Institute of Technology. Center for Biomedical Innovation
dc.contributor.departmentSloan School of Management
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2023-11-09T04:21:30Z
dc.language.rfc3066en
dc.rights.holderThe Author(s), under exclusive licence to Springer Nature Switzerland AG
dspace.embargo.termsY
dspace.date.submission2023-11-09T04:21:30Z
mit.licenseOPEN_ACCESS_POLICY
mit.metadata.statusAuthority Work and Publication Information Neededen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record